Form 4: CARLSMED CFO Greenstein Boosts Stake with RSU Grant

CARLSMED, Inc.'s CFO and Treasurer, Leonard M. Greenstein, acquired 44,977 shares of common stock through a restricted stock unit grant.

Summary

• Leonard M. Greenstein, the Chief Financial Officer and Treasurer of CARLSMED, INC. (CARL), acquired 44,977 shares of the company's common stock.
• This acquisition occurred on January 28, 2026, through a grant of Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of CARLSMED's Common Stock.
• The RSUs are structured to vest in three equal annual installments, with the first vesting occurring on the first anniversary of the grant date.
• Following this transaction, Greenstein's beneficial ownership of CARLSMED common stock totals 188,346 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management's interests with long-term shareholder value, without indicating any immediate operational changes.

Positives

• The RSU grant aligns the CFO's financial interests with the long-term performance of CARLSMED, incentivizing sustained commitment.
• Equity-based compensation like RSUs is a standard practice that can signal management's confidence in the company's future prospects.

Future Outlook

The RSUs granted to the CFO are structured to vest in three equal annual installments, beginning on the first anniversary of the grant date, indicating a long-term incentive structure designed to retain key management and align their interests with future company performance.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive compensation across various industries, particularly in growth-oriented technology and medical device companies like CARLSMED. This practice aims to align executive incentives with long-term company performance and shareholder interests, a standard in competitive talent markets.

Comparison to Industry Standards

• RSU grants are a standard component of executive compensation packages in the medical device industry, comparable to practices at companies like Medtronic, Stryker, and Intuitive Surgical, which also utilize equity awards to incentivize long-term performance.
• The vesting schedule of three equal annual installments is a common structure designed to retain executives and ensure sustained commitment, aligning with best practices observed in peer companies.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CFO's financial interests with long-term shareholder value through the vesting schedule, potentially fostering greater commitment to company performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs, impacting morale and retention.

Next Steps

• The RSUs will vest in three equal annual installments, with the first vesting occurring on the first anniversary of the grant date (January 28, 2027).

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event (RSU grant) and does not contain information that would fundamentally alter the investment thesis for CARLSMED. While it signals management alignment, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and consider this as part of the ongoing compensation structure.

Keywords

CARLSMED, CARL, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, CFO, Stock Grant, Beneficial Ownership